NeurOp, a pioneering brand in the field of NMDA receptor modulation, is at the forefront of developing innovative treatments for central nervous system (CNS) disorders. Founded in 2002 by renowned experts, NeurOp focuses on addressing conditions such as pain, stroke, subarachnoid hemorrhage, and severe depression through groundbreaking research and drug development. The brand's dedication to advancing neuropharmacology is reflected in its Management Team, Scientific Founders, and Board of Directors, who bring a wealth of expertise to the table.

NeurOp's lead compound, NP10679, is currently undergoing Phase 1 clinical trials with promising results, paving the way for Phase 2 testing in severe peri-operative pain and subarachnoid hemorrhage. With a commitment to creating more effective and safer medicines, NeurOp is poised to make significant strides in the treatment of CNS disorders. Visit their website for more information on their innovative approach